Soligenix Grants usage of US Patent for treatment of Oral Mucositis

Committed to developing and commercialising products to cure rare diseases proclaims granting US patent entitled Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis. The new US patent, number 9,850,270, issued on December 26, 2017 is an addition to the patent portfolio for dusquetide and would be expected to expire in 2034 .Having shown affirmative response in phase 2 oral mucositis clinical trial. Phase 3 study was conducted in 2017 where Therapeutic use of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs has been claimed .

Phase 2 results have shown positive results for treatment of oral mucositis in head and neck cancer patients. SGX942 at a dose of 1.5 mg/kg successfully lowered the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy for treatment of their HNC. Increased incidences of “complete response” of tumor at both the one month and twelve month follow-up visits were also witnessed followed by fall in infection and mortality rates.

Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix commented, “Having successfully pursued composition of matter claims in jurisdictions worldwide, we continue to pursue therapeutic use claims like those issued in the US with this most recent patent.  The therapeutic use claims are expected to be generally valid until 2034, which provides significant patent protection and life to dusquetide and our other IDR analogs.”